((自动化翻译由路透提供,请见免责声明 ))
路透伦敦10月8日 - 辉瑞公司 及其德国合作伙伴BioNTech公司 周二在伦敦高等法院赢得了对竞争对手CureVac公司 两项专利无效的诉讼。
辉瑞和BioNTech于2022年9月就信使RNA(mRNA) 技术的相关专利提起诉讼,该技术是辉瑞和BioNTech的COVID-19疫苗的基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.